Page 1460 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 80 Clinical Manifestations, Staging, and Treatment of Follicular Lymphoma 1297.e3

79. Herold M, Haas A, Srock S, et al: Addition of Rituximab to First-Line with increased risk of relapse after autologous bone marrow transplanta-
MCP (Mitoxantrone, Chlorambucil, Prednisolone) Chemotherapy tion for B-cell lymphoma. Blood 81:3449, 1993.
Prolongs Survival in Advanced Follicular Lymphoma 4 Year Follow-Up 99. Corradini P, Ladetto M, Zallio F, et al: Long-term follow-up of indolent
Results of a Phase III Trial of the East German Study Group Hematol- lymphoma patients treated with high-dose sequential chemotherapy
ogy and Oncology. Blood 108:147a, 2006. and autografting: evidence that durable molecular and clinical remis-
80. Foussard C, Mounier N, Van Hoof A, et al: Update of the FL2000 sion frequently can be attained only in follicular subtypes. J Clin Oncol
randomized trial combining rituximab to CHVP-Interferon in fol- 22:1460, 2004.
licular lymphoma (FL) patients (pts). J Clin Oncol 24:7508a, 2006. 100. Ladetto M, Vallet S, Benedetti F, et al: Prolonged survival and low
81. Schulz H, Bohlius J, Skoetz N, et al: Combined immunochemotherapy incidence of late toxic sequelae in advanced follicular lymphoma
with rituximab improves overall survival in patients with follicular and treated with a TBI-free autografting program: updated results of the
mantle cell lymphoma: updated meta-analysis results. Blood 108:781a, multicenter consecutive GITMO trial. Leukemia 20:1840, 2006.
2006. 101. Stone RM: Myelodysplastic syndrome after autologous transplantation
82. Lewis G, Marcus RE, Proctor SJG, et al: The Cost-effectiveness of for lymphoma: the price of progress? Blood 83:3437, 1994.
Rituximab, Cyclophosphamide, Vincristine, and Prednisolone (R-CVP) 102. Schouten HC, Qian W, Kvaloy S, et al: High-dose therapy improves
Compared with CVP for the Treatment of Follicular Non-Hodgkin’s progression-free survival and survival in relapsed follicular non-
Lymphoma (NHL) in the UK. Blood 108:107a, 2006. Hodgkin’s lymphoma: results from the randomized European CUP
83. Fisher RI, Kaminski MS, Wahl RL, et al: Tositumomab and iodine- trial. J Clin Oncol 21:3918, 2003.
131 tositumomab produces durable complete remissions in a subset 103. Gopal AK, Kahl BS, de Vos S, et al: PI3Kdelta inhibition by idelalisib
of heavily pretreated patients with low-grade and transformed non- in patients with relapsed indolent lymphoma. N Engl J Med 370:1008,
Hodgkin’s lymphomas. J Clin Oncol 23:7565, 2005. 2014.
84. Kaminski MS, Tuck M, Estes J, et al: 131I-tositumomab therapy as 104. Mossner E, Brunker P, Moser S, et al: Increasing the efficacy of CD20
initial treatment for follicular lymphoma. N Engl J Med 352:441, 2005. antibody therapy through the engineering of a new type II anti-CD20
85. Kaminski MS, Radford JA, Gregory SA, et al: Re-treatment with I-131 antibody with enhanced direct and immune effector cell-mediated
tositumomab in patients with non-Hodgkin’s lymphoma who had previ- B-cell cytotoxicity. Blood 115:4393, 2010.
ously responded to I-131 tositumomab. J Clin Oncol 23:7985, 2005. 105. Leonard JP, Schuster SJ, Emmanouilides C, et al: Durable complete
86. Press OW, Unger JM, Braziel RM, et al: Phase II trial of CHOP responses from therapy with combined epratuzumab and rituximab:
chemotherapy followed by tositumomab/iodine I-131 tositumomab final results from an international multicenter, phase 2 study in recur-
for previously untreated follicular non-Hodgkin’s lymphoma: five-year rent, indolent, non-Hodgkin lymphoma. Cancer 113:2714, 2008.
follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 106. Maddocks K, Christian B, Jaglowski S, et al: A phase 1/1b study of
24:4143, 2006. rituximab, bendamustine, and ibrutinib in patients with untreated and
87. Deconinck E, Foussard C, Milpied N, et al: High-dose therapy fol- relapsed/refractory non-Hodgkin lymphoma. Blood 125:242, 2015.
lowed by autologous purged stem-cell transplantation and doxorubicin- 107. Younes A, Thieblemont C, Morschhauser F, et al: Combination of
based chemotherapy in patients with advanced follicular lymphoma: a ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine,
randomized multicenter study by GOELAMS. Blood 105:3817, 2005. and prednisone (R-CHOP) for treatment-naive patients with CD20-
88. Witzig TE, Flinn IW, Gordon LI, et al: Treatment with ibritumomab positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b
tiuxetan radioimmunotherapy in patients with rituximab-refractory study. Lancet Oncol 15:1019, 2014.
follicular non-Hodgkin’s lymphoma. J Clin Oncol 20:3262, 2002. 108. Friedberg JW, Sharman J, Sweetenham J, et al: Inhibition of Syk with
89. Witzig TE, White CA, Gordon LI, et al: Safety of yttrium-90 ibritu- fostamatinib disodium has significant clinical activity in non-Hodgkin
momab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, lymphoma and chronic lymphocytic leukemia. Blood 115:2578,
or transformed non-Hodgkin’s lymphoma. J Clin Oncol 21:1263, 2003. 2010.
90. Freedman AS, Gribben JG, Neuberg D, et al: High dose therapy and 109. Wilson WH, O’Connor OA, Czuczman MS, et al: Navitoclax, a targeted
autologous bone marrow transplantation in patients with follicular high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1
lymphoma during first remission. Blood 88:2780, 1996. dose-escalation study of safety, pharmacokinetics, pharmacodynamics,
91. Horning SJ, Negrin RS, Hoppe RT, et al: High-dose therapy and and antitumour activity. Lancet Oncol 11:1149, 2010.
autologous bone marrow transplantation for follicular lymphoma in 110. van Besien K, Loberiza FR, Jr, Bajorunaite R, et al: Comparison of
first complete or partial remission: results of a phase II clinical trial. autologous and allogeneic hematopoietic stem cell transplantation for
Blood 97:404, 2001. follicular lymphoma. Blood 102:3521, 2003.
92. Lenz G, Dreyling M, Schiegnitz E, et al: Myeloablative radioche- 111. Toze CL, Barnett MJ, Connors JM, et al: Long-term disease-free
motherapy followed by autologous stem cell transplantation in first survival of patients with advanced follicular lymphoma after allogeneic
remission prolongs progression-free survival in follicular lymphoma: bone marrow transplantation. Br J Haematol 127:311, 2004.
results of a prospective, randomized trial of the German Low-Grade 112. Freytes CO, Loberiza FR, Rizzo JD, et al: Myeloablative allogeneic
Lymphoma Study Group. Blood 104:2667, 2004. hematopoietic stem cell transplantation in patients who experience
93. Al Khabori M, de Almeida JR, Guyatt GH, et al: Autologous stem relapse after autologous stem cell transplantation for lymphoma: a
cell transplantation in follicular lymphoma: a systematic review and report of the International Bone Marrow Transplant Registry. Blood
meta-analysis. J Natl Cancer Inst 104:18, 2012. 104:3797, 2004.
94. Freedman AS, Ritz J, Neuberg D, et al: Autologous bone marrow 113. Escalon MP, Champlin RE, Saliba RM, et al: Nonmyeloablative
transplantation in 69 patients with a history of low-grade B-cell non- allogeneic hematopoietic transplantation: a promising salvage therapy
Hodgkin’s lymphoma. Blood 77:2524, 1991. for patients with non-Hodgkin’s lymphoma whose disease has failed a
95. Freedman AS, Neuberg D, Mauch P, et al: Long-term follow-up of prior autologous transplantation. J Clin Oncol 22:2419, 2004.
autologous bone marrow transplantation in patients with relapsed 114. Morris E, Thomson K, Craddock C, et al: Outcomes after
follicular lymphoma. Blood 94:3325, 1999. alemtuzumab-containing reduced-intensity allogeneic transplantation
96. Apostolidis J, Gupta RK, Grenzelias D, et al: High-dose therapy with regimen for relapsed and refractory non-Hodgkin lymphoma. Blood
autologous bone marrow support as consolidation of remission in fol- 104:3865, 2004.
licular lymphoma: long-term clinical and molecular follow-up. J Clin 115. Gribben JG, Zahrieh D, Stephans K, et al: Autologous and allogeneic
Oncol 18:527, 2000. stem cell transplantations for poor-risk chronic lymphocytic leukemia.
97. Gribben JG, Freedman AS, Neuberg D, et al: Immunologic purging of Blood 106:4389, 2005.
marrow assessed by PCR before autologous bone marrow transplanta- 116. Shea T, Johnson J, Westervelt P, et al: Reduced-intensity allogeneic
tion for B-cell lymphoma. N Engl J Med 325:1525, 1991. transplantation provides high event-free and overall survival in patients
98. Gribben JG, Neuberg D, Freedman AS, et al: Detection by polymerase with advanced indolent B cell malignancies: CALGB 109901. Biol
chain reaction of residual cells with the bcl-2 translocation is associated Blood Marrow Transplant 17:1395, 2011.